- Home
- MOLN vs FENC Comparison
MOLN vs FENC Comparison
Compare MOLN & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MOLN | FENC |
|---|---|---|
| Founded | 2004 | 1996 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 158.9M | 266.4M |
| IPO Year | 2021 | 2010 |
Fundamental Metrics
Financial Performance| Metric | MOLN | FENC |
|---|---|---|
| Price | $3.93 | $5.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $8.38 | ★ $15.00 |
| AVG Volume (30 Days) | 3.4K | ★ 194.6K |
| Earning Date | 03-12-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $44,642,000.00 |
| Revenue This Year | N/A | $75.81 |
| Revenue Next Year | $318.52 | $25.06 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.36 | $4.68 |
| 52 Week High | $5.36 | $9.92 |
Technical Indicators
Market Signals| Indicator | MOLN | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 31.65 | 29.58 |
| Support Level | $3.51 | N/A |
| Resistance Level | $4.07 | $8.27 |
| Average True Range (ATR) | 0.26 | 0.49 |
| MACD | -0.08 | -0.20 |
| Stochastic Oscillator | 16.67 | 4.05 |
Price Performance
Historical ComparisonAbout MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.